Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

When the liver is badly scarred by cirrhosis, the consequences are not just digestive. It can creep up and affect your brain ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

A shorter course of prophylactic antibiotics, or even no course at all, appeared to be noninferior to longer courses in ...

In hospitalized patients with acute kidney injury and liver cirrhosis, baseline and peak levels of serum cystatin C can ...

With significant hedge fund interest and a share price under $10, 89bio, Inc. (NASDAQ:ETNB) secures a spot on our list of the ...

Prosecutors charged Blair Hamilton Hayes, 61 with causing the death of 47-year-old Emma Jean Teague this March ...

Indian scientists developed treatment for liver cirrhosis, accompanied by the distortion of both blood and lymphatic vessels in the liver and the intestine ...

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

Current guidelines for patients with cirrhosis and upper-GI bleeding recommend 5 to 7 days of antibiotic prophylaxis to ...